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Background:  A  high-coverage  public  health  prenatal  program  (70,000  women/year)  from  central  western
Brazil/Goias  State  has  represented  a unique  opportunity  for the  early  diagnosis  of HIV-1 and  implemen-
tation  of  strategies  to  prevent  mother-to-child  transmission  (MTCT).
Objectives:  To  investigate  MTCT  among  a prospective  cohort  of  HIV-1  infected  mothers/exposed  infants.
Study design:  142  mothers/their  149  infants  (2008–2010)  were  investigated  regarding  maternal  viral load,
CD4+cell  counts,  HIV-1  pol sequences;  infants’  HIV-1  RNA  tests  (30/120days),  sequential  anti-HIV-1/2
serology.  HIV-1  subtypes  were  assigned  by  REGA.  Transmitted  drug  resistance  was  identiﬁed  by  the Cali-
brated  Population  Resistance  tool,  secondary  resistance  by  Stanford  HIV-1  Drug  Resistance/International
AIDS  Society  databases.
Results: Mothers  (median  age =  24  years;  25/142  adolescents)  were  diagnosed  during  prenatal  care
(2008–2010)  or  previously  (1994–2007).  Recent  cases  were  younger,  mostly  asymptomatic.  Undetectable
viremia  and MTCT  prophylaxis  predominated  in  formerly  diagnosed  mothers.  Recent  cases  had  higher
subtype  C  prevalence.  One  naive  patient  had  transmitted  resistance;  ten  antiretroviral-experienced
patients  had  secondary  resistance:  6 from  MTCT  prophylaxis,  4 under  HAART.  Late  disclosure  of  diag-
nosis,  vaginal  delivery,  breastfeeding,  lack  of oral  zidovudine  were  observed  in  the  three  MTCT  cases
(3/149;  2.01%).  Two  of  three  infected  infants  harbored  subtype  C;  infected  infants/mothers  did  not
have  drug  resistance  mutations.  Two  of  the  transmitting-mothers  had  viremia  <1000  copies/ml.  Among
exposed-uninfected  infants  the median  time  to seroreversion  was  12 months.
Conclusions:  In this  study  delayed  disclosure  of diagnosis,  partial/no  preventive  measures,  drug  resistance
among  asymptomatic  women  under  prophylaxis  and  MTCT  in  low  viremic  mothers  raise  concerns.  The
expansion  of  subtype  C  infection  corroborates  surveillance  of  HIV-1  diversity  in this  region.. Background
HIV-1 mother-to-child-transmission (MTCT) is a multifactorial
vent in which high maternal viral load, low CD4+ cell counts, mode
f delivery, antiretroviral (ARV) therapy and prematurity play a
ole.1 Preventive strategies including prophylactic or therapeutic
Abbreviations: HIV-1, human immunodeﬁciency virus type 1; MTCT, mother-
o-child transmission; ARV, antiretroviral; PPPW, Program for the Protection of
regnant Women; HAART, highly active antiretroviral therapy; NRTI, nucleoside
everse-transcriptase inhibitors; NNRTI, nonnucleoside reverse-transcriptase; PI,
nhibitor protease; PR, protease; RT, reverse transcriptase; cDNA, complemen-
ary DNA; CPR, Calibrated Population Resistance Tool; IAS-USA, International AIDS
ociety-USA; CI, conﬁdence Interval; AZT, zidovudine; MDR, multidrugresistant.
∗ Corresponding author. Tel.: +55 62 3209 61 11; fax: +55 62 3209 63 63.
E-mail address: mariane.stefani@pq.cnpq.br (M.M.A. Stefani).
386-6532     © 2012 Elsevier B.V.  
oi:10.1016/j.jcv.2012.01.011
Open access under the Elsevier OA license.© 2012 Elsevier B.V.
ARV use, cesarian section and breastfeeding proscription can
reduce MTCT from 25% up to 1%.2,3 However, ARV treatment can
promote the selection and transmission of resistant mutants and
compromise prevention.4,5
Brazil was  the ﬁrst developing country to implement a coun-
trywide public health program to prevent HIV-1 MTCT, however
it still occurs.6,7 Routine prenatal HIV-1 screening represents a
unique circumstance for the early diagnosis and prevention of
MTCT. Nevertheless, missing opportunities can jeopardize preven-
tive measures.8
In Goias State, central western Brazil, a special public
health prenatal program (“Program for the Protection of Preg-
Open access under the Elsevier OA license.nant Women/PPPW”) implemented in 2003 screens ∼70,000
pregnant women/year from ∼240 municipalities. Serological
screening includes HIV-1, hepatitis B/C, Human T-Lymphotropic-
Virus, syphilis, toxoplasmosis, rubella, Chagas’ disease and
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ytomegalovirus. A survey among 28,561 pregnant women from
his regional Program showed an HIV-1 prevalence of 0.09% (95%
I 0.06%–0.14%).9 A recent report by the Ministry of Health showed
mportant regional differences in the rate of HIV-1 MTCT in Brazil:
ighest rate in southern (5.8%) and lowest rate (1%) in central west-
rn region.7
. Objectives
This prospective study among pairs of HIV-1 infected mothers
nd exposed infants from central western Brazil describes MTCT
nd related factors (prophylaxis, resistance mutations). HIV-1 sub-
ypes and seroreversion in exposed-uninfected children are also
eported.
. Study design
.1. Patients
During the study period (June/2008–June/2010), 146,897 preg-
ant women were screened by the PPPW/“Institute of Diagnoses
nd Prevention/IDP/APAE”, Goiania/Goias). Around 70% (148/198)
f conﬁrmed cases of HIV-1 infection were enrolled. This cohort
ncluded both recently and formerly diagnosed women as prena-
al screening includes all pregnant women, regardless of previous
IV-1 diagnosis. Enrollment occurred any time during pregnancy
r up to 30 days postpartum. Mother–infant pairs were prospec-
ively followed up (one year) at the main regional public hospital
or HIV-1 care (Anuar Auad Hospital, HAA/HDT/SUS). Epidemiolog-
cal data were collected in standardized forms; clinical, obstetric
ata were obtained from medical records. This research protocol
as approved by the institutional review board (“Comite de Etica
 Pesquisa HAA/HDT/SUS”, protocol #003/2008). All women pro-
ided informed consent for themselves and their newborns.
able 1
ain epidemiological, clinical and MTCT prophylaxis characteristics among newly diagno
Variable Recently diagnosed mothers (n = 65) 
Age at diagnosis (years)
Median (range) 25 (15–39) 
Clinical status at diagnosis n/N (%)
Asymptomatic (HIV) 56/62a (90.3.0) 
Symptomatic (AIDS) 06/62 (9.7) 
CD4+ cell counts (cells/mm3)A
Median (range) 543 (162-1418)c
Plasma viral loadA (copies/mL)
Median (n) 19,826 (35) 
Range  492–750,000 
Undetectable n (%) 22/57e (38.6) 
ARV  during pregnancyA n (%)
1st or 2nd trimester 38 (58.5) 
3rd  trimester 14 (21.5) 
No  ARV 13 (20.0) 
Maternal IV ZDV during laborA n/N (%)
Yes 56/62g (90.3) 
No  06/62 (9.7) 
Mode of deliveryA
Cesarian section n/N (%) 43/65 (66.1) 
Vaginal n/N (%) 22/65 (33.9) 
HIV-1 Subtypes in polB n/N (%)
B  25/40 (62.5) 
BF1  04/40 (10.0) 
C  09/40 (22.5) 
F1  02/40 (5.0) 
CB  00 (0.0) 
he P values were determined by Fisher’s exact test, Mann–Whitney or Spearman test, 
ata:  a = 03, b = 01; c = 08; d = 06; e = 08; f = 07; g = 03; h = 2.
A Spearman tests considering: ARV therapy as covariate to compare CD4+ T cell counts 
s  a covariate to compare prophylaxis, maternal intravenous ZDV use during labor and m
B Not ampliﬁed = 59.cal Virology 54 (2012) 15– 20
The standard highly active-antiretroviral-therapy/HAART regi-
men used for MTCT prophylaxis/treatment consisted of two  NRTIs:
zidovudine (ZDV)/3TC–Combivir® and one PI (LPV/ritonavir-
boosted–Kaletra®).10
3.2. Immunological and virological proﬁles
The classiﬁcation into asymptomatic/symptomatic was deﬁned
at diagnosis according to CDC AIDS-deﬁning conditions. CD4+ cell
counts (FACSCalibur, Becton & Dickson, San Jose, CA, USA), HIV-1
RNA tests (Amplicor HIV-1 Monitor test, version 1.5; Roche, USA)
were performed in maternal samples (last trimester-30 days post-
partum) and in infants (30, 120 days of life). MTCT diagnosis was
based on two  positive HIV-1 RNA tests in samples collected after
30 days of life. Two negative HIV-1 RNA tests (30/120 days of
life) excluded MTCT. Exposed-uninfected newborns were moni-
tored by anti-HIV-1/2 IgG ELISA (Wiener Laboratories, Argentina)
each 3–4 months throughout the ﬁrst 12 months or until serore-
version.
3.3. HIV-1 subtypes and resistance analysis in pol gene
Plasma RNA (mothers/infected newborns) was extracted, retro-
transcribed into complementary DNA (cDNA) and the entire HIV-1
protease (PR) and reverse transcriptase (RT) fragment (∼750-bp)
were ampliﬁed by nested polymerase chain reaction followed by
direct sequencing, as described.11 HIV-1 subtypes were identiﬁed
using REGA tool version 2.0.12
Transmitted drug resistance was  identiﬁed by the Cal-
ibrated Population Resistance tool13 secondary drug resis-
tance by the Stanford Surveillance Drug Resistance Muta-
tion/International AIDS Society-USA (IAS-USA) major muta-
tion list (Accessed: August/2011). GenBank accession num-
bers of the generated sequences are JN114115, JN114116,
sed mothers for HIV-1 infection and mothers diagnosed before index pregnancy.
Formerly diagnosed mothers (n = 77) P
23 (14–36) 0.04
54/76b (71.1) 0.04
22/76 (28.9)
499 (91–1931)d 0.21
5836 (27) 0.007
455- 312,349
43/70f (61.4) 0.01
56 (72.7) 0.04
08 (10.4)
13 (16.9)
72/75h (96.0) 0.16
03/75 (4.0)
63/77 (81.8) 0.05
14/77 (18.2)
29/43 (67.5) 0.40
09/43 (20.9) 0.14
02/43 (4.6) 0.02
02/43 (4.6) 0.66
01/43 (2.3) 0.51
as appropriate [CI 95% (p < 0.05)]; ARV = Antiretroviral; ZDV = zidovudine; Missing
and viral loads for the two groups (r = 0.11; r = 0.24, respectively); time of diagnosis
ode of delivery (r = −0.25; r = 0.22; r = 0.16, respectively).
f Clinical Virology 54 (2012) 15– 20 17
J
J
J
J
J
J
J
J
J
3
d
p
n
4
4
s
n
c
b
y
(
i
(
l
y
p
n
l
w
t
p
n
m
5
n
r
d
A
(
w
(
n
a
i
m
w
v
(
a
t
p
M
A
a
u
bs
ti
tu
ti
on
s 
in
 
th
e 
PR
 
(p
ro
te
as
e)
 
an
d
 
R
T 
(r
ev
er
se
 
tr
an
sc
ri
p
ta
se
) 
re
si
st
an
ce
-r
el
at
ed
 
co
d
on
s 
of
 
m
ot
h
er
s 
w
it
h
 
se
co
n
d
ar
y 
re
si
st
an
ce
 
to
 
an
ti
re
tr
ov
ir
al
 
d
ru
gs
.
Th
er
ap
y/
p
ro
p
h
yl
ax
is
 
Su
bt
yp
e 
Pr
ot
ea
se
 
in
h
ib
it
or
s 
(P
I)
 
R
ev
er
se
 
tr
an
sc
ri
p
ta
se
 
in
h
ib
it
or
 
m
u
ta
ti
on
s 
R
es
is
ta
n
ce
 
p
ro
ﬁ
le
M
aj
or
 
m
u
ta
ti
on
s 
M
in
or
 
m
u
ta
ti
on
s 
N
R
TI
 
N
N
R
TI
 
Lo
w
 
In
te
rm
ed
ia
te
 
H
ig
h
H
A
A
R
T 
th
er
ap
y 
B
/B
 
– 
– 
M
18
4V
 
– 
– 
– 
3T
C
/F
TC
H
A
A
R
T 
th
er
ap
y 
F1
/B
 
– 
– 
A
62
V
, M
18
4V
 
K
10
3 
N
, P
22
5H
 
3T
C
/F
TC
 
e
ET
R
 
– 
D
LV
/E
FV
/N
V
P
H
A
A
R
T 
th
er
ap
y 
F1
/B
 
– 
– 
M
18
4V
, T
21
5Y
 
K
10
3 
N
, P
22
5H
 
ZD
V
/D
4 
T/
D
D
I 
A
B
C
 
3T
C
/F
TC
 
e
D
LV
/E
FV
/N
V
P
H
A
A
R
T 
th
er
ap
y 
B
/B
 
D
30
N
, N
88
D
, L
90
M
 
A
71
 
T 
D
67
N
, K
70
R
, M
18
4V
, T
21
5Y
, K
21
9D
E 
L1
00
I, 
H
22
1Y
 
FP
V
r 
A
TV
r/
ID
V
r/
SQ
V
r 
N
FV
TD
F 
A
B
C
/D
4 
T/
D
D
I 
3T
C
/A
ZT
/F
TC
ET
R
 
D
LV
/E
FV
/N
V
P
H
A
A
R
T 
p
ro
p
h
yl
ax
is
a
B
/B
 
M
46
L,
 
I5
0L
, V
82
A
 
A
71
V
 
M
18
4V
 
– 
FP
V
r/
SQ
V
r 
ID
V
r/
LP
V
r 
A
TV
r/
N
FV
H
A
A
R
T 
p
ro
p
h
yl
ax
is
a
C
/C
 
– 
– 
M
18
4V
 
K
10
3 
N
 
– 
– 
3T
C
/F
TC
D
LV
/E
FV
/N
V
P
H
A
A
R
T 
p
ro
p
h
yl
ax
is
 
B
/B
 
I8
5V
 
– 
– 
– 
– 
– 
–
H
A
A
R
T 
p
ro
p
h
yl
ax
is
 
F1
/B
 
– 
– 
A
62
V
, T
69
A
, M
18
4M
 
– 
A
B
C
 
– 
3T
C
/F
TC
H
A
A
R
T 
p
ro
p
h
yl
ax
is
 
B
/B
 
– 
– 
– 
V
10
6I
, V
17
9D
, Y
18
8L
 
ET
R
 
D
LV
 
EF
V
/N
V
P
H
A
A
R
T  
p
ro
p
h
yl
ax
is
a
B
/F
1 
– 
– 
M
18
4V
 
E1
38
A
 
– 
– 
3T
C
/F
TC
in
h
ib
it
or
; 
N
R
TI
: 
n
u
cl
eo
si
d
e 
re
ve
rs
e 
tr
an
sc
ri
p
ta
se
 
in
h
ib
it
or
s;
 
N
N
R
TI
: 
n
on
-n
u
cl
eo
si
d
e 
re
ve
rs
e 
tr
an
sc
ri
p
ta
se
 
in
h
ib
it
or
s.
 
A
TV
: 
at
az
an
av
ir
; 
ZD
V
: 
zi
d
ov
u
d
in
e;
 
D
D
I:
 
d
id
an
os
in
e;
 
D
LV
: 
d
el
av
ir
d
in
e;
 
d
4 
T:
 
st
av
u
d
in
e;
 
EF
V
:
R
: 
et
ra
vi
ri
n
e;
 
FP
V
: 
fo
sa
m
p
re
n
av
ir
; 
ID
V
: 
in
d
in
av
ir
; 
LP
V
: 
lo
p
in
av
ir
; 
N
FV
: 
n
el
ﬁ
n
av
ir
; 
N
V
P:
 
n
ev
ir
ap
in
e,
 
SQ
V
: 
sa
qu
in
av
ir
.
it
h
 
fo
rm
er
 
d
ia
gn
os
is
 
w
h
ic
h
 
re
ce
iv
ed
 
M
TC
T 
p
ro
p
h
yl
ax
is
 
in
 
a 
p
re
vi
ou
s 
p
re
gn
an
cy
.K.C. Alcântara et al. / Journal o
N114118, JN114120, JN114124, JN114126, JN114127, JN114129,
N114130, JN114132–JN114138, JN114140–JN114145, JN114147,
N114149–JN114153, JN114155, JN114159, JN114162, JN114164,
N114168, JN1141, JN114170, JN114171, JN114173–JN114176,
N114178–JN114180, JN114182–JN114188, JN114190–JN114195,
N114199, JN114201, JN1142, JN114203, JN114206, JN114207,
N114209, JN114210, JN114217, JN114222, JN114225, JN114227,
N114229, JN114235; JN662426, JN662427, JN662429, JN662431,
N662434, JN662435.
.4. Statistical analyses
Descriptive analyses (frequency, medians, averages, standard
eviations) (Epi InfoTM Version 3.5.1) and univariate analyses were
erformed. Fisher Exact, Spearman, Kruskal Wallis or Mann Whit-
ey tests (95%CI, p-value < 0.05) were performed when appropriate.
. Results
.1. Characteristics of pregnant women infected with HIV-1
Among 148 pairs of HIV-1 infected mothers/exposed infants
tudied, six women were enrolled twice due to consecutive preg-
ancies; one mother gave birth to twins. Therefore this cohort
onsisted of 142 different mothers that delivered a total of 149 live
orn infants. No miscarriage or stillbirth was reported.
The median maternal age at diagnosis was 24 years (range 14–39
ears; sd = 5.3), adolescents (14–19 years old) represented 17.6%
25/142). Heterosexual transmission was reported by all partic-
pants; however 10.6% (15/142) referred blood transfusion, 2.1%
3/142) were intravenous drug users. Mothers had low educational
evel/income: 4.9% (7/142) were illiterate, 45.8% (65/142) had <8
ears of education, 23.9% (34/142) had a formal job with salary.
For the six mothers with consecutive pregnancies, data for both
regnancies were collected; Table 1 data refer to the ﬁrst preg-
ancy. Comparison of data from consecutive pregnancies indicated
ower CD4+ cell counts (5/6 women) and higher viral loads (3/6
omen) in the second pregnancy. Among the 12 babies born to
hese six mothers, one case of MTCT was diagnosed in the ﬁrst
regnancy of one of them.
The great majority of participants (83.8%; 119/142) were diag-
osed for HIV-1 during prenatal care: 65 from 2008 to 2010 at a
edian gestational age of 20 weeks (recently diagnosed group) and
4 were originally diagnosed from 1994 to 2007 (formerly diag-
osed group) (median time since diagnosis = 4 years; 1–14 years
ange). Among formerly diagnosed group only 16.2% (23/142) were
iagnosed for HIV-1 infection independently of a prenatal care.
mong recent cases, three women were diagnosed during labor
HIV1/2 rapid tests); for other three participants HIV-1 diagnosis
as disclosed 10 days postpartum.
Comparisons between recently/formerly diagnosed women
Table 1) indicate mostly asymptomatic women at the time of diag-
osis. However higher rate of symptomatic cases was observed
mong formerly diagnosed (28.9% vs 9.7%; p < 0.05), the major-
ty (49/77; 63.6%) was under ARV when they became pregnant,
ost (72.7% vs 58.5%) received early MTCT prophylaxis (p < 0.05),
hich correlated with higher rate of undetectable viremia (61.4%
s 38.6%) (p < 0.05). High access to intravenous ZDV during labor
>90%) and cesarian section predominated in both groups. Among
dolescent pregnant sub-group (n = 25), most (14/25) were mul-
iparous; 12/25 were diagnosed for HIV-1 during a previous
renatal care. Around 25% (6/25) of adolescents were symptomatic.
ost adolescents initiated early prophylaxis and all received
RV-prophylaxis/treatment. No MTCT case was observed among
dolescents. Ta
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.2. HIV-1 pol gene diversity, transmitted and secondary drug
esistance
Pol was sequenced in 58.4% (83/142) participants, all of them
rom central western Brazil (80 from Goias/3 from Mato Grosso
tate). Forty patients were recent diagnoses, 43 were formerly
iagnosed (Table 1). Interestingly HIV-1 subtype C prevalence was
igher among recent cases (22.5% vs 4.6%) (p < 0.05). Overall HIV-1
ubtype B predominated, followed by BF1 recombinants; similar
requency of subtype F1 (∼5%) was observed in both groups. HIV-1
ubtype B (n = 2) and one BF1 isolate were detected in patients from
ato Grosso.
Only 1 out of 17 ARV-naive patients presented transmitted resis-
ance: M46L PI mutation. In the ARV-experienced group, (57 under
rophylaxis; 9 under HAART), ten patients (15.2%) presented sec-
ndary drug resistance: six under prophylaxis, four under HAART
Table 2). Single class resistance mutations were observed in three
ecent cases under prophylaxis: PI (JN114173), NRTI (JN114190)
nd NNRTI (JN114207). In the prophylaxis group, 3 formerly diag-
osed patients submitted to previous prophylaxis presented dual
lass mutations: PI/NRTI (JN114118) and NRTI/NNRTI (JN114145,
N114227). In the HAART group NRTI mutation (JN114124),
able 3
ain characteristics of HIV-1 infected mothers/exposed infants (n = 149) and of three cas
All 
n  (%) 
Infant features 149 (100)
Gender 
F 73  (49)
M  76 (51)
Gestational age (weeks) 
Median (range) 38 (33–42)
Birth weight (g) 
Median 2970
(range) (1548–4710)
Mode of delivery
Cesarian 110 (73.8)
Vaginal 39 (26.2)
Oral ZDV 
Yes  143 (96.0)
No 06 (4.0)
Breastfeeding 
Yes  06 (4.0) 
No  143 (96.0)
CD4 T cell counts (cell/mm3) 
Median 2812
(range) (855–6500)
Age at HIV-1 diagnosis (days) NA 
Viral  load at diagnosis (copies/mL) NA 
Seroreversion (months)A
Median (range) 12 (1–18)
Maternal features 142 (100)
Clinical statusa
Asymptomatic (HIV) 86 (62.3)
Symptomatic (AIDS) 52 (37.7)
CD4 T cell countsb (cell/mm3)
Median 525
(range) (91–1931)
Plasma viral loadc (copies/mL) 
Median 10,209
(range) (455–750,000)
Undetectable 64
ARV during pregnancy 
1st  or 2nd trimester 94 (66.2)
3rd trimester 22 (15.5)
No  ARV 26 (18.3)
ZDV in labord
Yes  128 (93.4)
No 09 (6.6)
RV: antiretroviral; F = female; ZDV: zidovudine; IV: intravenous; NA: not available; miss
A 69 children followed up until seroreversion.cal Virology 54 (2012) 15– 20
NRTI/NNRTI mutations (JN114124, JN114132) and multidrug resis-
tance (MDR) (JN114143) were detected.
4.3. Main characteristics of HIV-1 exposed infants
Most HIV-1 exposed infants were males, <10% were premature
(<37 weeks) (Table 3). Around 6% (6/95) infants born to recently
diagnosed mothers were breastfed (∼10 days) and missed oral ZDV.
In this cohort the rate of HIV-1 MTCT was  2.01% (3/149) and asso-
ciated with late disclosure of maternal diagnosis that resulted in
two cases of vaginal delivery, one breastfed infant and one case did
not take oral ZDV. Among mother/infant pairs that missed oppor-
tunities to fully prevent MTCT, no clinical/laboratory differences
were observed among the ones that did not transmit (n = 48) and
the MTCT cases (n = 3) (data not shown). Interestingly two out of
three MTCT cases harbored HIV-1 subtype C; one was subtype B
(p < 0.05). None of the transmitting mothers/infected infants had
drug resistance mutations in pol.Almost half (69/146) of HIV-1 exposed-uninfected infants were
followed up until seroreversion that took place at a median age
of 12 months (1–18 months range). Maternal viremia, clinical sta-
tus, birth weight, gestational age had no impact on the time to
es of HIV-1 MTCT.
CASE CASE CASE
1 2 3
F F F
38 36 38
3095 2600 2430
Cesarian section Vaginal Vaginal
Yes No Yes
No Yes No
(10 days)
2175 NA 937
30 10 30
34,499 121,468 127,069
No No No
AIDS HIV AIDS
932 NA 303
862 2840 Undetectable
3rd trimester No ARV 3rd trimester
Yes No Yes
ing data: a = 4; b = 14; c = 15; d = 5.
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eroreversion. Seventy-seven HIV-1 exposed-uninfected children
id not comply with extended serological follow up after the early
xclusion of MTCT by molecular tests.
. Discussion
This prospective cohort study discloses important features of
IV-1 infected pregnant women and exposed infants from inland
oias State/central western Brazil, a setting that offers high pre-
atal access to diagnosis, treatment and MTCT prophylaxis. In
ummary, the proﬁles of pregnant women depicted here reﬂect the
urrent hallmark features of the HIV-1 epidemic in Brazil: “interior-
zation, heterosexualization, juvenilization and impoverishment”.
In our study, around 10% isolates from pregnant women under
rophylaxis or continuous HAART had drug resistance mutations.
hese results raise concerns regarding the efﬁcacy of future MTCT
rophylaxis/therapy for these patients. In our study the most preva-
ent NRTI M184V mutation, leads to resistance to 3TC and increases
usceptibility to ZDV/d4T.14,15 Two women under HAART had the
RTI T215Y mutation that removes ZDV and d4T incorporated
nto the DNA when associated with M184 V mutation. One MDR
atient under HAART had thymidine analogue resistance muta-
ions (TAMs) in codons 67/70/215 and accumulation of TAMs may
ead to cross-resistance between NRTIs.16 In this study none of
he HIV-1 transmitting mothers presented resistance mutations.
owever since our analyses were performed by bulk sequencing,
hich detects viral populations representing >20%, drug resistance
utations in minority viral populations cannot be excluded.17
The rate of HIV-1 MTCT observed here (∼2%) is lower than
escribed in other Brazilian studies, which also reported partial
ccess to prophylactic measures.18–23 In fact recent data showed
hat central western region has the lowest rate of HIV-1 MTCT in
razil.7 These results undoubtedly reﬂect the positive impact of the
ide and efﬁcient public health prenatal “Program for the Protec-
ion of Pregnant Women”, implemented by two  out three States
rom this region (Goias and Mato Grosso do Sul States).
High viremia during pregnancy/delivery is considered the main
isk factor for MTCT.24–27 However in our study, MTCT occurred
n the context of low maternal viremia. Despite the high prena-
al coverage/HIV-1 screening in the study area, the MTCT cases
bserved seemed to correspond to “missing opportunities” to fully
revent transmission.28,29 A previous regional study showed 40.8%
s 1% MTCT without and under adequate prophylaxis.29 In our
tudy, time of diagnosis also seemed a key event to MTCT outcome,
mphasizing the importance of early prenatal care for the diagno-
is and treatment/prophylaxis. Early ARV-intervention is crucial to
each undetectable viremia at delivery, which represents one of the
ornerstones in MTCT prevention.
The small number of infected children in this study is an
cknowledged limitation, indicating that multicentric cohort stud-
es are necessary to investigate risk factors associated with HIV-1
ertical transmission. Since most participants were either under
AART/prophylaxis and therefore had low/undetectable viremia,
round 60% had cDNA ampliﬁed and HIV-1 pol sequenced. Despite
his, it is noteworthy that higher prevalence of subtype C was
bserved among recent cases (13.2%) compared to formerly diag-
osed mothers and previous regional surveys (∼2.0%).18,30–32 The
urrent study presents the highest prevalence of subtype C detected
n central western Brazil so far. It is also remarkable that two (18.2%)
f the 11 mothers infected with subtype C transmitted the virus,
hile only one of the 72 mothers (1.4%) with “non-subtype C” trans-
itted HIV-1. While the role of different HIV-1 subtypes in vertical
ransmission is still debatable33–35 our study conﬁrms the interi-
rization of HIV-1 subtype C in inland Brazil among heterosexual
opulation.
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The data of HIV-1 infected pregnant women/newborns from
inland Brazil described here may  help deﬁne timely strategies
for earlier diagnosis/prophylaxis during prenatal care which are
fundamental to progress towards an HIV-free generation. The
dissemination of HIV-1 subtype C in an area where subtype
B predominates, emphasizes the need of continued molecular
surveillance studies in central western Brazil.
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